Zealand Pharma and its partner Boehringer Ingelheim have revealed detailed results from a Phase II study of the drug candidate survodutide for the treatment of fatty liver disease, or MASH.

The results show that the treatment had an effect in up to 83% of patients compared to 18.2% in the placebo group. 

In a secondary endpoint concerning liver fibrosis, which is liver scarring, survodutid also demonstrated an effect.

Up to 52.3% of adults with liver fibrosis showed improvement compared to 25.8% in the placebo group. 

In the moderate to advanced liver fibrosis group, up to 64.5% of patients improved compared to 25.9% in the placebo group, a stock exchange announcement reads. 

This is according to a stock exchange announcement ahead of a presentation of the data at a conference in Milan. A summary of the detailed results was briefly posted on the website of the scientific conference on Thursday. 

The Zealand Pharma share price rose 2.1% to DKK 665 (USD 95) on Friday after a gain of over 7% on Thursday.

English edit: Catherine Brett